Comprehensive Side Effects Guide

Last updated: March 7, 2026 — Data sourced from STEP, SURMOUNT, SUSTAIN, and SELECT clinical trial programs

Side Effects Incidence: STEP vs. SURMOUNT Trials

The following table compares adverse event incidence rates from the pivotal clinical trial programs for semaglutide (STEP 1–5) and tirzepatide (SURMOUNT-1–4). Rates are approximate and reflect pooled data from published results [1][2][3].

AE = adverse event. Rates are approximate and may vary across individual trials within each program. Source: published trial data [1][2][3].

Gastrointestinal Side Effects

GI side effects are the most common adverse events associated with GLP-1 receptor agonists. They result primarily from the delayed gastric emptying and central appetite suppression mechanisms of these drugs. The majority of GI side effects are transient and most pronounced during dose titration [4].

Nausea

Incidence: 30–44% | Typical duration: 3–7 days after each dose increase | Severity: Usually mild to moderate

Mechanism: GLP-1R activation in the area postrema (the brain's "vomiting center") and delayed gastric emptying contribute to nausea. The area postrema sits outside the blood-brain barrier and detects circulating GLP-1 analogs directly [5].

Management strategies:

• Eat smaller, more frequent meals (5–6 small meals instead of 2–3 large ones)
• Avoid high-fat, greasy, fried, or heavily spiced foods
• Eat slowly and stop at the first sign of fullness
• Ginger products (tea, chews, capsules) — evidence supports 1–1.5 g ginger daily for nausea relief [6]
• Stay upright for 30 minutes after eating
• Avoid strong odors that may trigger nausea
• If severe: your prescriber may recommend ondansetron (Zofran) or a slower titration schedule

Constipation

Incidence: 10–24% | Typical duration: May persist throughout treatment | Severity: Mild to moderate

Mechanism: Slowed GI motility due to delayed gastric emptying, combined with reduced food and fiber intake from appetite suppression [4].

Management strategies:

• Increase water intake to at least 64–80 oz daily
• Add fiber gradually (psyllium husk, chia seeds, vegetables) — target 25–30 g/day
• Regular physical activity (walking stimulates bowel motility)
• Osmotic laxative (MiraLAX / polyethylene glycol 3350) if needed — safe for daily use
• Stool softener (docusate sodium) for hard stools
• Magnesium citrate (200–400 mg) — also supports sleep and muscle recovery

Diarrhea

Incidence: 15–30% | Typical duration: Transient, usually 2–5 days | Severity: Mild to moderate

Mechanism: Altered GI motility patterns and bile acid metabolism changes. More common in early treatment [4].

Management strategies:

• Stay well hydrated — oral rehydration solutions if frequent
• BRAT diet (bananas, rice, applesauce, toast) during acute episodes
• Avoid dairy, caffeine, alcohol, and high-fat foods temporarily
• Probiotics may help restore gut flora balance
• Loperamide (Imodium) for acute relief if needed — consult your provider

Vomiting

Incidence: 6–25% | Typical duration: Episodic during dose increases | Severity: Variable

Mechanism: Same central mechanisms as nausea, often triggered by overeating or eating too quickly while on GLP-1 therapy [5].

Management strategies:

• Strict portion control — overeating is the most common trigger
• Eat slowly and chew food thoroughly
• Avoid carbonated beverages with meals
• If persistent: ondansetron (Zofran) 4–8 mg as needed, prescribed by your physician
• Seek medical attention if vomiting persists >24 hours or you cannot keep fluids down

Hepatobiliary Side Effects

Cholelithiasis (Gallstones)

Incidence: 0.6–1.6% (vs. 0.5% placebo) | Onset: Typically 6–18 months into treatment | Risk level: Low but clinically significant

Mechanism: Rapid weight loss of any cause increases biliary cholesterol saturation and reduces gallbladder motility, promoting gallstone formation. This is not unique to GLP-1 RAs — it occurs with any rapid weight loss intervention including bariatric surgery and very-low-calorie diets [7].

Risk factors: Female sex, age >40, rapid weight loss (>1.5 kg/week), history of gallstones, Native American or Hispanic ethnicity.

Management strategies:

• Report right upper quadrant pain, especially after meals, to your provider
• Adequate fat intake (do not go extremely low-fat, as dietary fat stimulates gallbladder emptying)
• Some prescribers recommend prophylactic ursodeoxycholic acid (ursodiol) for high-risk patients
• Cholecystectomy if symptomatic gallstones develop

Pancreatic Side Effects

Pancreatitis

Incidence: <0.2% | Severity: Potentially serious | Risk level: Rare

Mechanism: The exact mechanism is debated. Possible contributions include increased pancreatic duct pressure from stimulated exocrine secretion, or pre-existing subclinical pancreatic disease unmasked by the medication [8].

Warning signs: Severe, persistent epigastric pain radiating to the back, often accompanied by nausea and vomiting. Pain may worsen after eating.

Management: Discontinue GLP-1 RA immediately. Seek emergency medical care. Do not restart the medication if pancreatitis is confirmed.

Thyroid Concerns

Thyroid C-Cell Tumors (Medullary Thyroid Carcinoma)

Incidence in humans: No confirmed increase | Boxed warning: Yes (based on rodent data) | Risk level: Theoretical

Mechanism: In rodent studies, GLP-1 RAs caused dose-dependent C-cell hyperplasia and medullary thyroid carcinoma (MTC). However, human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells, and large epidemiological studies have not detected an increased MTC risk in humans [9].

Contraindications: Personal or family history of MTC, or Multiple Endocrine Neoplasia type 2 (MEN 2).

Monitoring: Report persistent neck swelling, difficulty swallowing, or persistent hoarseness to your physician. Routine calcitonin screening is not recommended for the general population on GLP-1 RAs.

Metabolic Side Effects

Hypoglycemia

Incidence (monotherapy): 1–3% | Incidence (with insulin/sulfonylureas): 15–30% | Severity: Variable

Mechanism: GLP-1 RAs stimulate insulin secretion in a glucose-dependent manner, so hypoglycemia is uncommon when used as monotherapy. However, when combined with insulin or sulfonylureas, the additive insulin-stimulating effect can cause clinically significant hypoglycemia [10].

Management strategies:

• If you also take insulin or a sulfonylurea, your prescriber should reduce those doses when starting a GLP-1 RA
• Recognize symptoms: shakiness, sweating, confusion, rapid heartbeat, hunger
• Treat with fast-acting carbohydrates (glucose tablets, juice, regular soda) — the "Rule of 15" (15 g carbs, recheck in 15 minutes)
• Carry glucose tablets or gel at all times if on combination therapy

Injection Site Reactions

Incidence: 3–7% | Severity: Usually mild | Duration: 1–3 days per episode

Mechanism: Local immune or irritant response to the injected formulation [11].

Symptoms: Redness, swelling, itching, or mild pain at the injection site.

Management strategies:

• Rotate injection sites systematically (abdomen, thigh, upper arm)
• Allow the pen to reach room temperature before injecting (30 minutes out of refrigerator)
• Ice the area before injection for 1–2 minutes to reduce discomfort
• Do not inject into areas that are bruised, scarred, or hardened
• Topical hydrocortisone cream if itching persists

Hair Loss (Alopecia)

Incidence: 3–6% (vs. <1% placebo) | Onset: Typically 3–6 months after starting treatment | Duration: Usually temporary

Mechanism: This is telogen effluvium — a form of temporary hair shedding triggered by rapid weight loss, caloric restriction, and physiological stress. It is not specific to GLP-1 RAs; it occurs with any significant weight loss intervention [12].

Management strategies:

• Ensure adequate protein intake (1.0–1.2 g/kg/day minimum)
• Check and supplement iron, zinc, biotin, and vitamin D if deficient
• Avoid crash dieting — maintain minimum 1,200 kcal/day for women, 1,500 kcal/day for men
• Hair typically regrows within 6–12 months once weight stabilizes
• Minoxidil (topical) may accelerate regrowth — consult your dermatologist

Fatigue & Low Energy

Incidence: 5–11% | Onset: Often during early titration | Duration: Typically improves within 2–4 weeks

Mechanism: Primarily attributable to reduced caloric intake rather than a direct pharmacological effect. The body requires time to adapt to lower energy intake and shift toward greater fat oxidation [13].

Management strategies:

• Ensure you are eating enough — severe caloric restriction worsens fatigue
• Prioritize complex carbohydrates and protein at each meal
• Stay hydrated (dehydration compounds fatigue)
• Maintain regular sleep hygiene (7–9 hours per night)
• Light exercise can paradoxically improve energy levels
• Check vitamin B12, iron, and thyroid levels if fatigue persists

Muscle Loss (Lean Mass Reduction)

Incidence: Expected with significant weight loss | Magnitude: ~25–40% of total weight lost may be lean mass | Duration: Ongoing during active weight loss

Mechanism: Caloric deficit, regardless of cause, leads to loss of both fat mass and lean mass. The ratio depends on the magnitude of the deficit, protein intake, and physical activity levels. In STEP 1, approximately 39% of weight lost was lean mass [14].

Management strategies:

• Resistance training 2–3 times per week (single most effective intervention)
• High protein intake: 1.2–1.6 g/kg/day, distributed across 3–4 meals
• Creatine monohydrate: 3–5 g/day — strong evidence for muscle preservation during caloric deficit [15]
• Adequate total calories: Do not under-eat excessively; work with a dietitian if needed
• Consider DEXA scan at baseline and periodically to monitor body composition